Clinical trial · Interventional
Real-time Identification of the Aberrant Left Hepatic Arterial Territory in the Liver Using Near-infrared Fluorescence Imaging
Real-time Identification of the Aberrant Left Hepatic Arterial Territory in the Liver Using Near-infrared Fluorescence Imaging: Prospective Study to Develop Decision Algorithm to Define the Preservation/Ligation of an Aberrant Left Hepatic Artery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
" Hepatic artery variants are occasionally seen, especially 20-30% of aberrant left hepatic artery. In radical gastrectomy, decision for aberrant left hepatic artery(ALHA) ligation should consider the oncologic safety and liver-related complication. Theoretically, the ALHA preservation is the most ideal in the aspect of liver function protection. However, it is technically difficult which consumes much time. Not only that, oncologic safety could be threatened as some soft tissues, including lymph nodes, could be remained while in preserving the ALHA. There has been no standardized method to evaluate the ALHA, and to decide whether preserve or ligate it. This prospective study has been designed to develop the decision algorithm to define the ALHA preservation/ligation, using near-infrared fluorescence imaging during surgery. "
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stomach Neoplasm | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Group1 | Procedure | — | UNRESOLVED |
| Group2 | Procedure | — | UNRESOLVED |
| Group3 | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group1
- description
- Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
- interventionNames
- Procedure: Group1
- type
- EXPERIMENTAL
- label
- Group2
- description
- Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
- interventionNames
- Procedure: Group2
- type
- EXPERIMENTAL
- label
- Group3
- description
- No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients diagnosed with gastric adenocarcinoma pathologically before surgery 2. Patients aged between 20 to 80 3. Patients with an ECOG 0 or 1 4. Patients who were confirmed the presence of aberrant left hepatic artery before or during surgery Exclusion Criteria: 1. Patients with abnormal liver function test befor surgery 2. Patients who diagnosed liver cirrhosis or infectious liver disease 3. Patients who underwent liver resection, or chemotherapy for gastric cancer 4. Patients planned for combined liver resection or cholecystectomy during gastrectomy
References
Publications (0)
Data not yet available